Tag Archives: business development

State of the Biotech Industry: Burrill’s Biotech 2013 Report

Burrill

To open his Super Session at the 2013 BIO International Convention, G. Steven Burrill, CEO of Burrill & Company, injected some humor for the hundreds of attendees in the audience, saying after 45 years in the biotech industry, 27 years authoring the Burrill State-of-the-Industry Report and 20 years of presenting the report at Convention, he was determined to get through 228 slides in 90 minutes. And, he delivered, providing a comprehensive snapshot of the industry Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managed Entry Trumps Risk Sharing

Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Ernst & Young’s Beyond Borders: Matters of Evidence

Super Session

Hundreds of attendees turned out to glean insights from findings outlined in Ernst & Young LLP’s (EY) 27th annual report on the biotechnology industry – Beyond borders: matters of evidence – officially launched at Tuesday morning’s Super Session at the 2013 BIO International Convention. The report was presented by Glen Giovannetti and Gautam Jaggi of EY’s Global Life Sciences Center, and the Super Session featured a panel of industry leaders, including: Brian Edelman, VP, Corporate Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions of therapeutic in-licensors and out-licensors were released today. The analysis looked at the meeting activity of 180 in-licensors attending the Chicago conference in terms of what therapeutic areas and stages of development were in highest demand. Of the 804 drug R&D companies, companies in Phase I/Rare Disease came out ahead as a group, with an average of >17 meetings/company. This was followed by Phase Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Venture Capital Trends

Venture Capital Trends

With industry data and numbers, results are always a mixed bag, says David Thomas, BIO’s Director of Industry Research & Analysis – and the latest on venture capital trends is no exception. In the U.S., biotech VC funding is flat, and start-up money is drying up. According to the National Venture Capital Association (NCVA), U.S. VC funding for biotech fell to $4.1 billion in 2012 (figure 1). This 17% drop was greater than the 10% Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,